Charles Schwab Investment Management Inc. Purchases 44,970 Shares of Enovis Co. (NYSE:ENOV)

Charles Schwab Investment Management Inc. raised its position in shares of Enovis Co. (NYSE:ENOV) by 7.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 645,789 shares of the company’s stock after purchasing an additional 44,970 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Enovis were worth $28,337,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ENOV. Confluence Investment Management LLC bought a new stake in shares of Enovis in the fourth quarter worth approximately $3,494,000. Geode Capital Management LLC grew its stake in shares of Enovis by 9.5% in the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock worth $39,678,000 after acquiring an additional 80,165 shares during the period. UMB Bank n.a. grew its stake in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Enovis in the third quarter worth approximately $1,050,000. Finally, Jane Street Group LLC grew its stake in shares of Enovis by 247.6% in the third quarter. Jane Street Group LLC now owns 106,684 shares of the company’s stock worth $4,593,000 after acquiring an additional 75,988 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Price Performance

ENOV stock opened at $39.23 on Tuesday. Enovis Co. has a one year low of $35.14 and a one year high of $62.79. The company’s fifty day moving average price is $43.21 and its 200-day moving average price is $43.67. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a market capitalization of $2.23 billion, a PE ratio of -17.91 and a beta of 2.05.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. On average, equities analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reduced their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, February 27th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.